- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. freshman Avg
|
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We hereby consent to the incorporation by reference in the Registration Statement Nos.333-116629,333-109893,333-159247,333-198070,333-176306, and333-176305 on FormS-8, and Registration Statement Nos.333-194747,333-172849,333-150898,333-148911,333-132459,333-118907,333-115118,333-111650,333-109887,333-208674 and333-213138, on FormS-3 of our report dated March 28, 2017 included in this Annual Report on Form10-K of Galectin Therapeutics, Inc. and subsidiaries (the “Company”) relating to the consolidated balance sheets of the Company as of December 31, 2016, and the related consolidated statements of operations, changes in redeemable convertible preferred stock and stockholders’ equity, and cash flows for each of the two years in the period ended December 31, 2016.
/S/ CHERRY BEKAERT LLP
Atlanta, Georgia
March 28, 2017